Log in or Sign up for Free to view tailored content for your specialty!
Leukemia News
Novel T-cell therapy effective against common viruses after stem cell transplantation
Posoleucel demonstrated encouraging efficacy against common viral infections among patients who underwent allogeneic hematopoietic stem cell transplantation, according to phase 2 study results published in Clinical Cancer Research.
Cumulative anesthesia exposure linked to impaired neurocognitive function in pediatric ALL
NEW ORLEANS — Cumulative anesthesia exposure appeared associated with impairments in neurocognitive function among children with high-risk acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: ASAP trial 'could challenge standard of care' for relapsed/refractory AML
NEW ORLEANS — In this video perspective, Richard M Stone, MD, discusses data from the randomized phase 3 ASAP trial, which was presented at ASH Annual Meeting and Exposition.
VIDEO: Blinatumomab 'clearly positive' for minimal residual disease-negative ALL
NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research results on blinatumomab presented at ASH Annual Meeting and Exposition.
Imetelstat confers durable transfusion independence in lower-risk myelodysplastic syndrome
Imetelstat conferred a “highly statistically significant and clinically meaningful benefit” vs. placebo in enabling certain patients with myelodysplastic syndrome to achieve transfusion independence, according to the agent’s manufacturer.
Novel regimen significantly lowers GVHD risk after reduced-intensity allogeneic HSCT
NEW ORLEANS — A regimen containing post-transplant cyclophosphamide significantly lowered graft-versus-host disease risk among adults who underwent reduced-intensity allogeneic hematopoietic stem cell transplant, study results showed.
Tool may help identify which patients with clonal hematopoiesis will develop cancer
NEW ORLEANS — A new clinical tool can help identify which patients with clonal hematopoiesis are at highest risk for progression to cancer, according to study results presented at ASH Annual Meeting and Exposition.
Combination may benefit certain patients with TP53-mutated myelodysplastic syndrome
NEW ORLEANS — A higher burden of mutant TP53 cells connoted poorer risk among adults with intermediate- or high-risk myelodysplastic syndrome, according to study results presented at ASH Annual Meeting and Exposition.
BLOG: CAR T cells for long-term cure in pediatric ALL
Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
ASH recognizes Choosing Wisely, Guideline Implementation champions
ASH recognized three Choosing Wisely champions and three guideline implementation champions at this year’s ASH Annual Meeting and Exposition.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read